Literature DB >> 23256698

Assessment of regulatory T-cell function in forthcoming clinical trials of cell therapy.

James B Canavan, Behdad Afzali, Graham M Lord, Giovanna Lombardi.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23256698      PMCID： PMC3815565          DOI： 10.1586/erm.12.133

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN： 1473-7159            Impact factor:   5.225


× No keyword cloud information.
  20 in total

1.  A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles.

Authors:  Pratip K Chattopadhyay; Joanne Yu; Mario Roederer
Journal:  Nat Med       Date:  2005-09-25       Impact factor: 53.440

Review 2.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

3.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

4.  Rapid assessment of in vitro expanded human regulatory T cell function.

Authors:  Joyce J Ruitenberg; Christopher Boyce; Ravi Hingorani; Amy Putnam; Smita A Ghanekar
Journal:  J Immunol Methods       Date:  2011-07-18       Impact factor: 2.303

5.  In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells.

Authors:  Satish N Nadig; Joanna Wieckiewicz; Douglas C Wu; Gregor Warnecke; Wei Zhang; Shiqiao Luo; Alexandru Schiopu; David P Taggart; Kathryn J Wood
Journal:  Nat Med       Date:  2010-05-16       Impact factor: 53.440

6.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.

Authors:  T Takahashi; Y Kuniyasu; M Toda; N Sakaguchi; M Itoh; M Iwata; J Shimizu; S Sakaguchi
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

7.  First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.

Authors:  Piotr Trzonkowski; Maria Bieniaszewska; Jolanta Juścińska; Anita Dobyszuk; Adam Krzystyniak; Natalia Marek; Jolanta Myśliwska; Andrzej Hellmann
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

8.  Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model.

Authors:  Fadi Issa; Joanna Hester; Ryoichi Goto; Satish N Nadig; Tim E Goodacre; Kathryn Wood
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

9.  Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells.

Authors:  Pervinder Sagoo; Niwa Ali; Garima Garg; Frank O Nestle; Robert I Lechler; Giovanna Lombardi
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

10.  Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.

Authors:  Tatiana N Golovina; Tatiana Mikheeva; Todd M Brusko; Bruce R Blazar; Jeffrey A Bluestone; James L Riley
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240
View more
  2 in total

1.  Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.

Authors:  James B Canavan; Cristiano Scottà; Anna Vossenkämper; Rimma Goldberg; Matthew J Elder; Irit Shoval; Ellen Marks; Emilie Stolarczyk; Jonathan W Lo; Nick Powell; Henrieta Fazekasova; Peter M Irving; Jeremy D Sanderson; Jane K Howard; Simcha Yagel; Behdad Afzali; Thomas T MacDonald; Maria P Hernandez-Fuentes; Nahum Y Shpigel; Giovanna Lombardi; Graham M Lord
Journal:  Gut       Date:  2015-02-24       Impact factor: 23.059

Review 2.  Gene and cell therapy for children--new medicines, new challenges?

Authors:  Karen F Buckland; H Bobby Gaspar
Journal:  Adv Drug Deliv Rev       Date:  2014-02-28       Impact factor: 15.470
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.